(last updated August 2022)
In June 2021, I left Celgene*/BMS to join GSK’s Oncology R&D, Experimental Medicine Unit (EMU), Advanced Analytics group. Prior to joining GSK, I worked at Celgene/BMS for three years from 2018 to 2021. Before joining Celgene in June 2018, I was a postdoctoral researcher at McGill’s Human Genetics department. At McGill, I worked on genomics and epigenomics of pediatric brain cancer at Dr. Majewski’s group in collaboration with Dr. Jabado’s group at McGill (some other collaborator include research groups at Washington University, Columbia University, University of Toronto, Rockefeller University to name a few).
I joined Celgene in June 2018 as a scientist working with epigenetics informatics group (part of the predictive science group) remotely from Montreal.
In March 2019, as I was promoted to senior scientist, my geographical location changed as well and since, I have been living in Cambridge, MA.
My main focus these days are cancer epigenetics, immuno-oncology, and their intersection.
To see a complete list of my publications, please refer to my publications page or my google scholar page.
For the sake of privacy and respect of my current and previous pharmaceutical employers, I cannot disclose the projects I have been working on since June 2018.
* Celgene was acquired by Bristol-Myers Squibb (BMS) in 2019 and is a BMS company since November 28, 2020.